TRIM17 is upregulated in cisplatin-resistant lung cancer tissues and cells and reduces cisplatin sensitivity of lung cancer cells by promoting ubiquitination and degradation of RBM38 protein [18]. Here, RBM38 is linked to lung carcinoma.